Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress

Toxicology Mechanisms and Methods

Volumn 17, Issue 5, 2007, Pages 281-288

  Khoshakhlagh, Pooneh ^a   Bahrololoumi Shapourabadi, Mina ^a   Mohammadirad, Azadeh ^a   Ashtaral Nakhai, Leila ^a   Minaie, Bagher ^b   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cells; Inflammatory Bowel Disease; Lipid Peroxidation; Molecular Mechanism; Myeloperoxidase; Oxidative Stress; Phosphodiesterase Inhibitors; Sildenafil

Indexed keywords

ACETIC ACID; MYELOPEROXIDASE; PHOSPHODIESTERASE V INHIBITOR; PREDNISOLONE; SILDENAFIL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; ENTERITIS; ENZYME ACTIVITY; HISTOLOGY; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 34250750653     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510601003769     Document Type: Article

References (56)

1. Abdollahi, M., Bahreini-Moghadam, A., Emami, B., Fooladian, F., and Zafari, K. 2003b. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp. Biochem. Physio. C. Toxicol. Pharmacol. 135:331-336.
2. Abdollahi, M., Chan, T. S., Subrahmanyam, V., and O'Brien, P. J. 2003a. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol. Cell. Biochem. 252:205-211.
3. Abdollahi, M., Fooladian, F., Emami, B., Zafari, K., and Bahreini-Moghadam, A. 2003c. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum. Exp. Toxicol. 22:587-592.
4. Abdollahi, M., Ranjbar, A., Shadnia, S., Nikfar, S., and Rezaiee, A. 2004. Pesticides and oxidative stress. Med. Sci. Monit. 10:RA144-RA147.
5. Abdollahi, M., and Simaiee, B. 2003. Stimulation by theophylline and sildenafil of rat submandibular secretion of protein, epidermal growth factor and flow rate. Pharmacol. Res. 48:445-449.
6. Aghababaeian, R., Ghazi-Khansari, M., Abdi, K., Taghadosinejad, F., and Abdollahi, M. 2005. Protective effects of sildenafil and dipyridamol from lead-induced lipid peroxidation in perfused rat liver. Intl. J. Pharmaol. 1:157-160.
7. Ahnfelt-Ronne, I., and Nielsen, O. H. 1987. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents. Actions. 21:191-194.
8. Allgayer, H. 1991. Clinical relevance of oxygen radicals in inflammatory bowel disease-facts and fashion. Klin. Wochenschr. Rev. 69:1001-1003.
9. Arnhold, J. 2004. Properties, functions, and secretion of human myeloperoxidase. Biochemistry. (Mosc). 69:4-9.
10. Banner, K. H., and Trevethick, M. A. 2004. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends. Pharmacol. Sci. Rev. 25:430-436.
11. Barbosa, D. S., Cecchini, R., El Kadri, M. Z., Rodriguez, M. A., Burini, R. C., and Dichi, I. 2003. Decreased oxidative stress in patients with ulcerative colitis supplemente with fish oil omega-3 fatty acids. Nutrition 19:837-842.
12. Bortolotti, M., Mari, C., Lopilato, C., La,, Rovere, L., and Miglioli, M. 2001. Sildenafil inhibits gastroduodenal motility. Aliment. Pharmacol. Ther. 15:157-161.
13. Dias-Junior, C. A., Souza-Costa, D. C., Zerbini, T., da Rocha, J. B., Gerlach, R. F., and Tanus-Santos, J. E. 2005. The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth. Analg. 101:115-120.
14. D'Odorico, A., Bortolan, S., Cardin, R., D'Inca', R., Martines, D., Ferronato, A., and Sturniolo, G. C. 2001. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand. J. Gastroenterol. 36:1289-1294.
15. Elson, C. O., Cong, Y., Brandwein, S., Weaver, C. T., McCabe, R. P., Mahler, M., Sundberg, J. P., and Leiter, E. H. 1998. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann. N. Y. Acad. Sci. 859:85-95.
16. Elson, C. O., Sartor, R. B., Tennyson, G., and Riddell, R. H. 1995. Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367.
17. Ghafari, H., Yasa, N., Mohammadirad, A., Minaie, B., Zamani, M. J., Nikfar, S., Dehghan, G. H., Khorasani, R., and Abdollahi, M. 2006. Protection by Ziziphora Clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum. Exp. Toxicol. 25:325-332.
18. Ghazanfari, G., Minaie, B., Yasa, N., Ashtaral-Nakhai, L., Mohammadirad, A., Nikfar, S., Dehghan, G., Shetab-Boushehri, V., Jamshidi, H., Khorasani, R., Salehnia, A., and Abdollahi, M. 2006. Biochemical and histopathological evidences for beneficial effects of Satureja Khuzestanica Jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol. Mech. Methods 16(7):365-372.
19. Gibson, P. R., and Iser, J. 2005. Inflammatory bowel disease. Aust. Fam. Physician 34:233-237.
20. Grisham, M. B. 1994. Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859-861.
21. Gupta, R. C. 2006. In: et al (Ed.), Toxicology of Organophosphates and Carbamate Compounds, Elsevier Academic Press, San Diego.
22. Hadjibabaie, M., Rastkari, N., Rezaie, A., and Abdollahi, M. 2005. The adverse drug reaction in the gastrointestinal tract: an overview. Intl. J. Pharmacol. 1:1-8.
23. Hatoum, O. A., Miura, H., and Binion, D. G. 2003. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am. J. Physiol. Heart. Circ. Physiol. Rev. 285:H1791-1796.
24. Jagtap, A. G., Shirke, S. S., and Phadke, A. S. 2004. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J. Ethnopharmacol. 90:195-204.
25. Jahanshahi, G., Motavasel, V., Rezaie, A., Hashtroudi, A. A., Daryani, N. E., and Abdollahi, M. 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci. 49:1752-1757.
26. Jeremy, J. Y., Angelini, G. D., Khan, M., Mikhailidis, D. P., Morgan, R. J., Thompson, C. S., Bruckdorfer, K. R., and Naseem, K. M. 2000. Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc. Res. Rev. 46:50-54.
27. Jurjus, A. R., Khoury, N. N., and Reimund, J. M. 2004. Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods 50:81-92.
28. Katzung, B. G. 2000. Basic & Clinical Pharmacology. Appleton & Lange; 8th edition.
29. Koupparis, A. J., Jeremy, J. Y., Muzaffar, S., Persad, R., and Shukla, N. 2005. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU. Int. 96:423-427.
30. Koutroubakis, I. E., Malliaraki, N., Dimoulios, P. D., Karmiris, K., Castanas, E., and Kouroumalis, E. A. 2004. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig. Dis. Sci. 49:1433-1437.
31. Krawisz, J. E., Sharon, P., and Stenson, W. F. 1984. Qualitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350.
32. Kruidenier, L., Kuiper, I., Van Duijn, W., Mieremet-Ooms, M. A., van Hogezand, R. A., Lamers, C. B., and Verspaget, H. W. 2003. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J. Pathol. 201:17-27.
33. Kvietys, P. R., Inauen, W., Bacon, B. R., and Grisham, M. B. 1989. Xanthine oxidase-induced injury to endothelium: role of intracellular iron and hydroxyl radical. Am. J. Physiol. 257:H1640-1646.
34. Langtry, H. D., and Markham, A. 1999. Sildenafil: a review of its use in erectile dysfunction. Drugs. Rev. 57:967-989.
35. Lih-Brody, L., Powell, S. R., Collier, K. P., Reddy, G. M., Cerchia, R., Kahn, E., Weissman, G. S., Katz, S., Floyd, R. A., McKinley, M. J., Fisher, S. E., and Mullin, G. E. 1996. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci. 41:2078-2086.
36. Lindsey, I., George, B., Kettlewell, M., and Mortensen, N. 2002. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis. Colon Rectum 45:727-732.
37. MacPherson, B., and Pfeiffer, C. J. 1976. Experimental colitis. Digestion 14:424-452.
38. McKenzie, S. J., Baker, M. S., Buffinton, G. D., and Doe, W. F. 1996. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest. 98:136-141.
39. Milani, E., Nikfar, S., Khorasani, R., Zamani, M. J., and Abdollahi, M. 2005. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 140:251-255.
40. Muzaffar, S., Shukla, N., Lobo, C., Angelini, G. D., and Jeremy, J. Y. 2004. Iloprost inhibits superoxide formation and gp91phox expression induced by the thromboxane A2 analogue U46619, 8-isoprostane F2alpha, prostaglandin F2alpha, cytokines and endotoxin in the pig pulmonary artery. Br. J. Pharmacol. 141:488-496.
41. Nielsen, O. H., and Ahnfelt-Ronne, I. 1991. Involvement of oxygen-derived free radicals in the pathogenesis of chronic inflammatory bowel disease. Klin. Wochenschr. Rev. 69:995-1000.
42. Noronha-Blob, L., Lowe, V. C., Muhlhauser, R. O., and Burch, R. M. 1993. NPC 15669, an inhibitor of neutrophil recruitment, is efficacious in acetic acid-induced colitis in rats. Gastroenterology 104:1021-1029.
43. Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. Rev. 347:417-429.
44. Radfar, M., Larijani, B., Hadjibabaie, M., Rajabipour, B., Mojtahedi, A., and Abdollahi, M. 2005. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacoth. 59:302-306.
45. Rezaie, A., Taghavi, B., and Abdollahi, M. 2005. Biologic management of fistulizing Crohn's disease. Intl. J. Pharmacol. 1:17-24.
46. Rosen, R. C., and Kostis, J. B. 2003. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am. J. Cardiol. Rev. 92:9M-18M.
47. Saiki, T. 1998. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume. Med. J. 45:69-73.
48. Satho, K. 1978. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin. Chem. Acta. 90:37-43.
49. Sharon, P., and Stenson, W. F. 1985. Metabolism of arachidonic acid in acetic acid colitis in rats. Gastroenterology 88:55-63.
50. Shukla, N., Jones, R., Persad, R., Angelini, G. D., and Jeremy, J. Y. 2005. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation inhypercholesterolaemic rabbits. Eur. J. Pharmacol. 517:224-231.
51. Simmonds, N. J., Millar, A. D., Blake, D. R., and Rampton, D. S. 1999. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther. 13:363-372.
52. Soderling, S. H., and Beavo, J. A. 2000. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell. Biol. Rev. 12:174-179.
53. Souness, J. E., Aldous, D., and Sargent, C. 2000. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol. Rev. 47:127-162.
54. Tuzun, A., Erdil, A., Inal, V., Aydin, A., Bagci, S., Yesilova, Z., Sayal, A., Karaeren, N., and Dagalp, K. 2002. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin. Biochem. 35:569-572.
55. Wakefield, A. J., Sankey, E. A., Dhillon, A. P., Sawyerr, A. M., More, L., Sim, R., Pittilo, R. M., Rowles, P. M., Hudson, M., and Lewis, A. A. 1991. Granulomatous vasculitis in Crohn's disease. Gastroenterology 100:1279-1287. Erratum in Gastroenterology 101:595
56. Zamani, M. J., Sharifzadeh, M., Rezaie, A., Mashayekhi, F., and Abdollahi, M. 2005. Effects of sildenafil on rat irritable bowel syndrome. Therapy 2:237-242.